Telix Pharmaceuticals posts $245m Q3 revenue, closes ITM merger

Telix reported 19% year-on-year revenue growth in Q3 2026 and confirmed its $1.65bn merger with isotope supplier ITM, targeting over $1bn in

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit modern conference room features a long wooden table lined with laptops, water glasses, and notebooks, surrounded by grey chairs, a large screen displaying an abstract design on the far wall, and expansive windows offering a c

Telix Pharmaceuticals has reported group revenue of US$245 million for the third quarter ended 30 September 2026, up 19% on the prior corresponding period, as the dual-listed Australian radiopharmaceutical company prepares to close a transformational merger with Isotope Technologies Munich SE (ITM).

The result was driven by the company's Precision Medicine division, which generated US$201 million in the quarter, a 30% year-on-year increase, largely on the back of continued demand for its PSMA-PET imaging agents Gozellix and Illuccix. The Telix Manufacturing Solutions segment contributed US$44 million, down 6% year-on-year.

FDA approval and pipeline progress

The quarter brought a significant regulatory milestone: the US Food and Drug Administration approved Pixclara (floretyrosine F 18) for glioma imaging, making it the first approved imaging agent for that indication in the US. The first commercial doses were administered in September 2026, and Telix has since filed a cleared IND to support a Phase 3 trial aimed at expanding the Pixclara label to cover brain metastases.

Progress continued across the broader pipeline. The BiPASS Phase 3 study of 68Ga-PSMA-11 PET combined with MRI for pre-biopsy prostate cancer detection completed enrolment of 350 patients, with the FDA having granted Fast Track Designation and supported an NDA pathway. The OPTIMAL-PSMA Phase 2 study of TLX597-Tx in metastatic androgen pathway modulator-resistant prostate cancer also completed enrolment of 120 patients, with a data readout expected in the first half of 2027. In glioblastoma, the IPAX-2 Phase 1 study of TLX101-Tx met its primary endpoint, establishing a maximum tolerated dose and supporting advancement to Phase 2.

ITM merger and full-year outlook

The most significant corporate development of the quarter was Telix's announced merger with ITM, described by the company as creating a vertically integrated radiopharmaceutical platform. The transaction carries upfront consideration of US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders receiving approximately US$1.25 billion in Telix shares issued as ADRs, plus contingent consideration of up to US$700 million tied to regulatory approvals and commercial milestones for ITM's lead asset, ITM-11 (177Lu-edotreotide), which targets gastroenteropancreatic neuroendocrine tumours. A shareholder vote is expected on 1 December 2026.

Managing Director and Group CEO Christian Behrenbruch said the merger creates "a leading vertically integrated radiopharmaceutical company with one of the industry's broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities."

Telix reaffirmed full-year 2026 revenue guidance at US$950 million to US$970 million, with revenue tracking toward the upper end of that range. Including other income of US$40 million, the company expects total revenue and other income to exceed US$1 billion. R&D expenditure guidance has been tightened to US$240 million to US$260 million.

Market context

The radiopharmaceutical sector has attracted substantial capital and consolidation activity over the past two years, with larger pharma groups pursuing vertically integrated models to secure isotope supply chains. Telix's move to acquire ITM's lutetium-177 production infrastructure directly addresses one of the sector's most cited operational constraints: reliable isotope access at commercial scale. The deal also broadens Telix's therapeutic pipeline beyond prostate and kidney cancers into neuroendocrine tumours, a segment with growing clinical interest since the approval of Lutathera. Investors will be monitoring the December shareholder vote closely, given the size of the consideration relative to Telix's current market capitalisation, and will look for early commercial traction from Pixclara as a near-term revenue diversifier.

Sector

Topic

Geography